Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CARM
DateTimeSourceHeadlineSymbolCompany
12/02/202518:02Business WireCarmila: Lancement d’un programme de rachat d’actions pour 10 millions d’eurosNASDAQ:CARMCarisma Therapeutics Inc
12/02/202518:02Business WireCarmila: Launch of a Share Buyback Program for €10 MillionNASDAQ:CARMCarisma Therapeutics Inc
11/02/202517:01Business WireCarmila : Résultats annuels 2024 : une croissance soutenue portée par l’acquisition de Galimmo et la dynamique commercialeNASDAQ:CARMCarisma Therapeutics Inc
11/02/202517:01Business WireCarmila: 2024 Annual Results: Sustained Growth Driven by the Acquisition of Galimmo and Strong Leasing MomentumNASDAQ:CARMCarisma Therapeutics Inc
10/02/202516:45Business WireCarmila: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
10/02/202516:45Business WireCarmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
05/02/202512:30PR Newswire (US)Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:CARMCarisma Therapeutics Inc
30/01/202521:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
14/01/202517:31Business WireCarmila: Resources Devoted to the Liquidity Contract as of 31 December 2024NASDAQ:CARMCarisma Therapeutics Inc
14/01/202517:31Business WireCarmila : Moyens portés au contrat de liquidité au 31 décembre 2024NASDAQ:CARMCarisma Therapeutics Inc
13/01/202512:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
10/01/202521:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
09/01/202516:45Business WireCarmila Will Publish Its 2024 Full-year Results on Tuesday, February 11, 2025, After Market CloseNASDAQ:CARMCarisma Therapeutics Inc
09/01/202516:45Business WireCARMILA: Information concerning the total number of voting rights and shareNASDAQ:CARMCarisma Therapeutics Inc
09/01/202516:45Business WireCarmila publiera ses résultats annuels 2024 le mardi 11 février 2025, après clôture des marchésNASDAQ:CARMCarisma Therapeutics Inc
09/01/202516:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
02/01/202521:28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
26/12/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
09/12/202413:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
09/12/202413:30PR Newswire (US)Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize PipelineNASDAQ:CARMCarisma Therapeutics Inc
05/12/202416:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
05/12/202416:45Business WireCARMILA: Information concerning the total number of voting rights and shareNASDAQ:CARMCarisma Therapeutics Inc
27/11/202412:30PR Newswire (US)Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:CARMCarisma Therapeutics Inc
17/11/202412:30PR Newswire (US)Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024NASDAQ:CARMCarisma Therapeutics Inc
08/11/202412:30PR Newswire (US)Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular CarcinomaNASDAQ:CARMCarisma Therapeutics Inc
07/11/202412:39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARMCarisma Therapeutics Inc
07/11/202412:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
07/11/202412:30PR Newswire (US)Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CARMCarisma Therapeutics Inc
06/11/202416:45Business WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
06/11/202416:45Business WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CARM